Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Xinran Ma,* Ling Li,* Lei Zhang, Xiaorui Fu, Xin Li, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Xiaoyan Feng, Yu Chang, Zhiyuan Zhou, Feifei Nan, Jieming Zhang, Zhaoming Li, Mingzhi Zhang Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis an...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2020-01-01
Series:Drug Design, Development and Therapy
Assuntos:
apatinib
relapsed or refractory diffuse large b-cell lymphoma
vegfr-2
efficacy
safety
Acceso en liña:https://www.dovepress.com/apatinib-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell--peer-reviewed-article-DDDT
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares